Monthly Archives: July 2016

Biotech’s Paradox: A Robustly Valued, Highly Active, And Seemingly Terrible IPO Market
July 14, 2016

After five very strong years, biotech as a sector has struggled to catalyze positive investor sentiment so far for the past twelve months. In a disastrous start to the year, the NASDAQ Biotech Index shed 30% in just the first

Leave a comment

Standing On The Shoulders Of Stem Cell Gene Therapists: History, Hyperbole And Hope For The Future
July 7, 2016

This post was written by Jason Gardner, Atlas EIR and CEO of Magenta Therapeutics, as part of the From The Trenches feature of LifeSciVC. A new type of medicine was approved in Europe at the end of May that culminated

Leave a comment

Life After The Street: Why Biotech Is Winning Over Wall Street Talent
July 5, 2016

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the From The Trenches feature of LifeSciVC. About three weeks ago, I attended a dinner organized by a good friend and former sell-side competitor, Dr. Yaron

1 Comment